STO · BICO.ST
BICO Group AB (publ)
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
Loading market information…
STO · ONCO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Oncopeptides AB (publ)’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Oncopeptides AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:39 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Feb 27, 2025 | -SEK 0.39 | SEK 9.91M-17.38% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -SEK 0.29 | SEK 8.51M-39.24% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
SEK 21.80-SEK 0.20 (-0.91%)
Genovis AB’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 68.30+SEK 0.40 (+0.59%)
Infant Bacterial Therapeutics AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 19.55% below the high.
SEK 58.70-SEK 0.30 (-0.51%)
I-Tech AB’s quoted price sits in the lower half of its reported 52-week range, 27.35% below the high.
SEK 10.70+SEK 0.22 (+2.1%)
Xspray Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 70.4% below the high.
SEK 3.20+SEK 0.40 (+14.08%)
Senzime AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
SEK 1.67+SEK 0.20 (+13.2%)
Cantargia AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
